Research Papers:

This article has been corrected. Correction in: Oncotarget. 2023; 14:83-84.

Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6

Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller, Stefanie Krassnig, Margit Gogg-Kamerer, Nadine Gantenbein, Anna M. Toeglhofer, Christina Wodlej, Helmut Bergler, Brigitte Pertschy, Stefan Uranitsch, Magdalena Holter, Amin El-Heliebi, Julia Fuchs, Andreas Punschart, Philipp Stiegler, Marlen Keil, Jens Hoffmann, David Henderson, Hans Lehrach, Christoph Reinhard, Christian Regenbrecht, Rudolf Schicho, Peter Fickert, Sigurd Lax and Johannes Haybaeck _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:101224-101243. https://doi.org/10.18632/oncotarget.20642

Metrics: PDF 1936 views  |   HTML 3306 views  |   ?  


Nicole Golob-Schwarzl1,2, Caroline Schweiger1, Carina Koller1, Stefanie Krassnig1, Margit Gogg-Kamerer1, Nadine Gantenbein1,2, Anna M. Toeglhofer1, Christina Wodlej1,2, Helmut Bergler3, Brigitte Pertschy3, Stefan Uranitsch4, Magdalena Holter5, Amin El-Heliebi6, Julia Fuchs6, Andreas Punschart7, Philipp Stiegler7, Marlen Keil8, Jens Hoffmann8, David Henderson9, Hans Lehrach10, Christoph Reinhard11, Christian Regenbrecht12, Rudolf Schicho13, Peter Fickert14, Sigurd Lax15 and Johannes Haybaeck1,2,16

1Institute of Pathology, Medical University of Graz, Graz, Austria

2Center for Biomarker Research in Medicine, Graz, Austria

3Institute of Molecular Biosciences, Karl-Franzens-University of Graz, Graz, Austria

4Department of Surgery, Hospital Brothers of Charity Graz, Graz, Austria

5Institute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria

6Institute of Cell Biology, Histology and Embryology, Medical University Graz, Graz, Austria

7Department of Surgery, Medical University of Graz, Graz, Austria

8Experimental Pharmacology & Oncology Berlin GmbH-Berlin-Buch, Berlin, Germany

9Bayer AG, Berlin, Germany

10Max Planck Institute for Molecular Genetics, Berlin, Germany

11Eli Lilly & Company, Indianapolis, USA

12Cpo – cellular phenomics & oncology Berlin-Buch GmbH, Berlin, Germany

13Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria

14Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria

15Department of Pathology, Hospital Graz South-West, Austria

16Department of Pathology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

Correspondence to:

Johannes Haybaeck, email: [email protected]

Keywords: colorectal carcinoma; liver metastases; eukaryotic translation initiation factors; PI3K/AKT/mTOR pathway

Received: January 05, 2017    Accepted: July 31, 2017    Published: September 05, 2017


Colorectal cancer (CRC) is the third most common cause of cancer related death worldwide. Furthermore, with more than 1.2 million cases registered per year, it constitutes the third most frequent diagnosed cancer entity worldwide. Deregulation of protein synthesis has received considerable attention as a major step in cancer development and progression. Eukaryotic translation initiation factors (eIFs) are involved in the regulation of protein synthesis and are functionally linked to the phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway.

The identification of factors accounting for colorectal carcinoma (CRC) development is a major gap in the field. Besides the importance of eIF3 subunits and the eIF4 complex, eIF1, eIF5 and eIF6 were found to be altered in primary and metastatic CRC. We observed significant difference in the expression profile between low and high grade CRC. eIF1, eIF5 and eIF6 are involved in translational control in CRC. Our findings also indicate a probable clinical impact when separating them into low and high grade colon and rectum carcinoma.

eIF and mTOR expression were analysed on protein and mRNA level in primary low and high grade colon carcinoma (CC) and rectum carcinoma (RC) samples in comparison to non-neoplastic tissue without any disease-related pathology. To assess the therapeutic potential of targeting eIF1, eIF5 and eIF6 siRNA knockdown in HCT116 and HT29 cells was performed. We evaluated the eIF knockdown efficacy on protein and mRNA level and investigated proliferation, apoptosis, invasion, as well as colony forming and polysome associated fractions.

These results indicate that eIFs, in particular eIF1, eIF5 and eIF6 play a major role in translational control in colon and rectum cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20642